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Abstract
Background: Resistant hypertension is independently associated with an increased risk of death in the general
hypertensive population. We assessed whether resistant hypertension is an independent predictor of all-cause mortality
in individuals with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre
Study.
Methods: On 31 October 2015, vital status information was retrieved for 15,656 of the 15,773 participants enrolled in
2006–2008. Based on baseline blood pressure (BP) values and treatment, participants were categorized as normotensive,
untreated hypertensive, controlled hypertensive (i.e., on-target with < 3 drugs), uncontrolled hypertensive (i.e., not
on-target with 1–2 drugs), or resistant hypertensive (i.e., uncontrolled with > 3 drugs or controlled with > 4 drugs).
Kaplan–Meier and Cox proportional hazards regression analyses were used to assess the association with all-cause
mortality.
Results: Using the 130/80mmHg targets for categorization, crude mortality rates and Kaplan–Meier estimates were
highest among resistant hypertension participants, especially those with controlled resistant hypertension. As compared
with resistant hypertension, risk for all-cause mortality was significantly lower for all the other groups, including individuals
with controlled hypertension (hazard ratio 0.81 [95% confidence interval 0.74–0.89], P < 0.0001), but became progressively
similar between resistant and controlled hypertension after adjustment for cardiovascular risk factors and complications/
comorbidities. Also when compared with controlled resistant hypertension, mortality risk was significantly lower for all the
other groups, including controlled hypertension, even after adjusting for cardiovascular risk factors (0.77 [0.63–0.95],
P = 0.012), but not for complications/comorbidities (0.88 [0.72–1.08], P = 0.216). BP was well below target in the controlled
hypertensive groups (resistant and non-resistant) and values < 120/70mmHg were associated with an increased mortality
risk. Results changed only partly when using the 140/90mmHg targets for categorization.
Conclusions: In the RIACE cohort, at variance with the general hypertensive population, resistant hypertension did not
predict death beyond target organ damage. Our findings may be explained by the high mortality risk conferred by type
2 diabetes and the low BP values observed in controlled hypertensive patients, which may mask risk associated with
resistant hypertension. Less stringent BP goals may be preferable in high-risk patients with type 2 diabetes.
Trial registration: ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July, 2008.
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Background
Type 2 diabetes is associated with excess mortality mainly,
though not exclusively attributable to cardiovascular dis-
ease (CVD) [1]. The increased risk for CVD morbidity
and mortality associated with type 2 diabetes requires a
prompt recognition and management of the other comor-
bidities clustering with hyperglycemia and contributing to
this high-risk profile, as demonstrated by the efficacy of
multifactorial intervention in the Steno-2 study [2, 3]. In
particular, control of hypertension represents a major
issue, even though blood pressure (BP) targets are still a
matter of debate, with recommended values ranging from
< 130 to < 140mmHg for systolic BP and from < 80 to
< 90 mmHg for diastolic BP [4]. Unfortunately, though
awareness and control of hypertension have improved
in the last decades, a high percentage of diabetic hyperten-
sive patients does not reach target BP levels [5, 6].
According to the 2008 Scientific Statement from the
American Heart Association (AHA) [7], resistant hyper-
tension is defined as uncontrolled BP despite the use of ≥
3 anti-hypertensive medication classes or controlled BP
while treated with ≥ 4 anti-hypertensive medication clas-
ses, with all agents prescribed at optimal dose amounts;
ideally, one of these classes should be a diuretic. A recent
revision of the AHA Scientific Statement has established
that, in addition to a diuretic, the anti-hypertensive regi-
men should include also a long-acting calcium channel
blocker (CCB) and a blocker of the renin-angiotensin sys-
tem (RAS) [8]. Pooled data from North America and
Europe indicated that 14.8% of treated hypertensive pa-
tients and 12.5% of all hypertensive individuals have
resistant hypertension [9]. However, these prevalence
estimates refer to “apparent resistant hypertension,” as
population-based studies are unable to distinguish cases
of “true resistant hypertension” from those of “pseudo-re-
sistant hypertension,” i.e., individuals with “white coat”
hypertension, non-adherence to medications, inappropri-
ately prescribed anti-hypertensive regimen, and incorrect
BP measurement due to cuff-related artifacts [10]. It has
been estimated that individuals with pseudo-resistant
hypertension are as many as those with true resistant
hypertension [10], who however should include also pa-
tients with BP uncontrolled with < 2 drugs who would fail
to achieve BP goal if treated with three drugs [11]. Sub-
jects with resistant hypertension are usually older, more
frequently obese and diabetic, and those with a higher
prevalence of target organ damage, including CVD and
chronic kidney disease (CKD), whereas data on gender
and ethnicity are contrasting [7, 10–23].
A few longitudinal studies demonstrated that resistant
hypertension is an independent predictor of all-cause
and CVD mortality, CVD morbidity, and end-stage renal
disease in the general hypertensive population, though
different definitions of resistant and non-resistant
hypertension were used [13–15, 18]. The increased risk
remained after adjustment for several confounders, includ-
ing CVD risk factors and target organ damage [13–15, 18].
In addition, some of these studies reported a worse prog-
nosis in uncontrolled resistant hypertension (i.e., BP not
on-target with ≥ 3 drugs) than in controlled resistant
hypertension (i.e., BP on-target with ≥ 4 drugs) [13, 14, 18].
An independent association between resistant hyperten-
sion and adverse outcomes was also reported in hyperten-
sive individuals with CVD [19–21] or CKD [22, 23].
Although the presence of diabetes has been invariably
reported among predictors of adverse outcomes in
hypertensive individuals [12–15, 18–22], only one study
has reported a subgroup analysis in diabetic patients
[18] and, so far, no study has evaluated the risk of death
associated with resistant hypertension in a type 2 dia-
betes population. We have previously reported that
prevalence of resistant hypertension was 17.4% among
hypertensive individuals and 21.2% among treated hyper-
tensive patients with type 2 diabetes from the Renal In-
sufficiency And Cardiovascular Events (RIACE) Italian
Multicentre Study [24].
The present analysis aimed at assessing whether resist-
ant hypertension at baseline is an independent predictor
of subsequent death from any cause in individuals with
type 2 diabetes from the RIACE cohort. To this end, in-
dividuals without hypertension or with non-resistant
hypertension were compared with patients with resistant
hypertension as reference group.
Methods
Design
The RIACE Italian Multicentre Study is an observa-
tional, prospective, cohort study on the impact of esti-
mated glomerular filtration rate (eGFR) on morbidity
and mortality in individuals with type 2 diabetes [25].
Study population
The study population included 15,773 Caucasian patients
(after excluding 160 individuals with missing or implaus-
ible values), consecutively attending 19 hospital-based,
tertiary referral Diabetes Clinics of the National Health
Service throughout Italy in the years 2006–2008.
Exclusion criteria were dialysis or renal transplantation.
The vital status of the participants on 31 October
2015 was verified by interrogating the Italian Health
Card database (http://sistemats1.sanita.finanze.it/wps/
portal/), which provides updated and reliable informa-
tion on all current Italian residents.
Measurements
At baseline, study participants underwent a structured
interview in order to collect the following information:
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age, smoking status, known diabetes duration, comor-
bidities, and current treatments.
Body mass index (BMI) was computed from weight and
height, whereas waist circumference was calculated from
log-transformed BMI values using sex-specific linear re-
gression equations derived from waist measurements ob-
tained in 4618 individuals. BP was measured with a
sphygmomanometer after a 5-min rest. Two consecutive
readings were taken 10min apart by a trained observer with
the patients seated with the arm at the heart level and the
cuff correctly placed on the arm circumference. Standard
adult cuffs were used (9–13 in.), except for severely obese
patients, where large cuffs (13–17 in.) were employed. The
second readings were used for the analysis [24]. Pulse pres-
sure, a surrogate measure of arterial stiffness, was then cal-
culated from systolic and diastolic BP values.
Triglycerides and total and HDL cholesterol were mea-
sured in fasting blood samples by colorimetric enzymatic
method, and LDL cholesterol was calculated by the
Friedewald formula. Hemoglobin (Hb) A1c was measured
by high-performance liquid chromatography using DCCT-
aligned methods.
Diabetic kidney disease (DKD) was assessed based on
albuminuria and eGFR. Albumin excretion rate (AER)
was measured from 24-h urine collections or estimated
from albumin-to-creatinine ratio in early-morning,
first-voided urine samples, using a conversion formula
developed in patients with type 1 diabetes [25, 26]. Albu-
minuria was measured in fresh urine samples by immu-
nonephelometry or immunoturbidimetry. For each
individual, one to three measurements were obtained; in
cases of multiple measurements, the geometric mean
was used for analysis. In subjects with multiple measure-
ments (4062 with at least two and 2310 with three
values), concordance rate between the first value and the
geometric mean was > 90% for all albuminuria classes
[26]. Serum (and urine) creatinine was measured by the
modified Jaffe method, traceable to IDMS, and estimated
eGFR was calculated by the CKD Epidemiology Collab-
oration equation [25]. Patients were then classified into
the Kidney Disease: Improving Global Outcomes A1–A3
and G1–G5 categories and further stratified into the
following DKD phenotypes, as previously reported [25]:
no DKD (i.e., G1A1–G2A1), albuminuria alone
(albuminuric DKD with preserved eGFR, i.e., G1A2–
G2A2–G1A3–G2A3), reduced eGFR alone (nonalbumi-
nuric DKD, i.e., G3A1–G4A1–G5A1), or albuminuria
and reduced eGFR (albuminuric DKD with reduced
eGFR, i.e., G3A2–G4A2–G5A2–G3A3–G4A3–G5A3).
In each center, presence of diabetic retinopathy (DR)
was evaluated by an expert ophthalmologist by dilated
fundoscopy. Based on the worst eye, individuals with
mild or moderate non-proliferative DR were classified as
having non-advanced DR, whereas those with severe
non-proliferative DR, proliferative DR, or maculopathy
were grouped into the advanced DR category, as previ-
ously reported [27].
Previous major acute CVD events (myocardial infarc-
tion, stroke, foot ulcer/gangrene/amputation, coronary,
carotid, lower limb revascularization, and surgery for
aortic aneurysm) were adjudicated based on hospital dis-
charge records [28].
Categorization of patients
Patients were stratified according to either the BP targets
of < 130/80 mmHg, recommended for diabetic individ-
uals at the time BP measures were obtained [29] and re-
cently confirmed by the American College of Cardiology
and AHA guidelines [30], or to the less stringent BP tar-
gets of < 140/90mmHg, which are currently established
by the American Diabetes Association, except for
high-risk individuals [31]. The following groups were
identified [24]: normotensive (NT); untreated hyperten-
sive (UTHT); hypertensive on-target with 1, 2, or 3
drugs (controlled hypertension; CHT); hypertensive not
on-target with 1 or 2 drugs (uncontrolled hypertension;
UCHT); and hypertensive not on-target with > 3 drugs
or on-target with > 4 drugs (resistant hypertension;
RHT). The RHT group was further divided into two sub-
groups, based on whether patients were on-target with
> 4 drugs (controlled resistant hypertension; CRHT) or
were not on-target with > 3 drugs (uncontrolled resistant
hypertension; UCRHT).
Statistical analysis
Data are expressed as mean ± SD or median (interquar-
tile range) for continuous variables, and number of cases
and percentage for categorical variables. Comparisons
among groups were performed by one-way ANOVA or
Kruskal–Wallis test, according to the parametric or
non-parametric distribution of continuous variables,
followed by Bonferroni correction or Mann–Whitney
test, respectively, for post hoc comparisons. The Pear-
son’s χ2 test was used for categorical variables.
Crude mortality rates were described as events per
1000 patient years, with 95% exact Poisson confidence
intervals (CIs); death rates were also adjusted for age
and gender by a Poisson regression model. Kaplan–
Meier survival probabilities for all-cause mortality were
estimated according to the above categorizations and
differences were analyzed using the log-rank statistic.
The hazard ratios (HRs) and their 95% CIs were esti-
mated by Cox proportional hazards regression, un-
adjusted and adjusted for baseline age and gender
(model 1); age, gender, and CVD risk factors, i.e.,
smoking status, diabetes duration, HbA1c, BMI, waist
circumference, triglycerides, total and HDL cholesterol,
and anti-hyperglycemic and lipid-lowering treatment
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(model 2); and age, gender, CVD risk factors, and com-
plications/comorbidities, i.e., DKD phenotypes, DR
grade, any CVD, and any cancer (model 3). In separate
analyses, models were further adjusted for either BP or
pulse pressure values at baseline to assess whether the
excess risk associated with RHT was attributable to the
higher levels of these parameters detected in RHT versus
CHT participants. All the above analyses were repeated
by including in the RHT group only patients on a diur-
etic or a CCB/RAS blocker/diuretic combination, ac-
cording to the 2008 [7] and 2018 [8] definition of
resistant hypertension, respectively. Finally, additional
analyses, adjusted for age and gender, were performed to
explore the relation between categories of on-treatment
BP values and mortality. In all the above analyses, the
RHT (or CRHT) group was used as reference to allow
comparison with all other groups, i.e., NT and the vari-
ous non-RHT groups (and UCRHT), thus distinguishing
patients with CHT from those with UTHT or UCHT,
who might include RHT individuals.
Results
Overall mortality in the study population
Valid information on vital status was retrieved for 15,656
participants (99.3% of the cohort). At the time of the cen-
sus, 12,054 (77.0%) patients were alive, whereas 3602
(23.0%) individuals had died; death rate was 31.0 per 1000
person years (95% CI 30.0, 32.0) over a median follow-up
of 8.0 years (interquartile range 7.5–8.5) [32, 33].
Clinical features of the study population (based on the
130/80 mmHg BP targets)
The RIACE participants with RHT were 15.0% of the
whole cohort (17.5% of all hypertensive individuals); of
them, 13.5% were on-target with > 4 drugs (CRHT) and
86.5% were not on-target with > 3 drugs (UCRHT). As
previously reported [24], RHT individuals were older,
more often females and former smokers, and more fre-
quently on insulin, lipid-lowering, anti-platelet, and
anti-coagulant treatment, as compared to patients classi-
fied into the other groups. In addition, they had longer
diabetes duration (except versus UCHT), lower eGFR,
and higher BMI, waist circumference, triglycerides, albu-
minuria, and prevalence of DKD, advanced DR, and
CVD (any and by vascular bed) (Table 1). Among RHT
patients, CRHT participants had lower eGFR and HDL
cholesterol and higher triglycerides and prevalence of
CVD, driven by coronary events, and were more often
on insulin and anti-coagulant therapy than UCRHT indi-
viduals, who were older and had higher total and LDL
cholesterol (Additional file 1: Table S1).
By definition, BP levels were higher in UTHT, UCHT,
RHT, and UCRHT than in NT, CHT, and CRHT partici-
pants (Tables 2 and 3). Interestingly, values in CHT and
CRHT individuals were well below 130/80mmHg. Use of
antihypertensive agents was significantly higher in RHT
versus the other treated hypertensive groups for any class
as well as in CRHT versus UCRHT individuals for RAS,
α-, and β-blockers and diuretics (Henle’s loop and
anti-aldosterone). Of note, pulse pressure was higher in
UCHT, RHT, and, to a lesser extent, UTHT individuals
versus the other groups and, within the RHT group, in
UCRHT versus CRHT participants, as for BP values.
Association between resistant hypertension and mortality
(based on the 130/80mmHg BP targets)
Crude mortality rates and Kaplan–Meier estimates were
highest for RHT, intermediate for CHT and UCHT, and
lowest for NT and UTHT participants (Table 4 and
Additional file 2: Figure S1A). Differences in mortality
rates (Table 4) were reduced after adjustment for age
and gender. When compared to RHT, CHT was
associated with a significantly lower risk of death only
in the unadjusted analysis (HR 0.81 [95% CI 0.81–0.89],
P < 0.0001) (Fig. 1a), whereas no difference was observed
after adjustment for age and gender (model 1; Fig. 1b) and
further adjustment for CVD risk factors (model 2; Fig. 1c)
and complications/comorbidities (model 3; Fig. 1d). Inter-
estingly, crude mortality rates (Table 4) and Kaplan–Meier
estimates (not shown) were highest for CRHT. Differences
in mortality rates were attenuated after adjustment for age
and gender (Table 4). As compared with CRHT individ-
uals, unadjusted HRs (Fig. 2a) were significantly lower in
all other groups (except UCRHT), including CHT partici-
pants (0.72 [0.59–0.87], P = 0.001). Differences between
RHT and CHT were maintained after adjustment for age
and gender (0.70 [0.57–0.86], P < 0.0001) (Fig. 2b), were
attenuated when adjusting also for CVD risk factors (0.77
[0.63–0.95], P = 0.012) (Fig. 2c), and disappeared when
accounting for complications/comorbidities (0.88 [0.72–
1.08], P = 0.216) (Fig. 2d). No change was observed when
further adjusting for BP or pulse pressure values or when
only RHT individuals on a diuretic or a CCB/RAS
blocker/diuretic combination were included in the analysis
(not shown).
Clinical features of the study population (based on the
140/90 mmHg BP targets)
When the cohort was stratified according to the 140/90
mmHg BP targets, the percentage of individuals with
RHT decreased (11.6% of the whole cohort and 14.9% of
all hypertensive individuals), with a higher proportion of
CRHT (30.7%), but the distribution of clinical parame-
ters among study groups and subgroups did not change
appreciably (Additional file 1: Tables S1 and Add-
itional file 3: Table S2). However, the average BP values
of the controlled hypertensive groups (CHT and CRHT)
became closer to 130/80 mmHg, as several individuals
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Table 1 Baseline clinical features in the RIACE participants with valid information on vital status, stratified by BP status according to
the 130/80 mmHg BP targets
Variable NT UTHT CHT UCHT RHT P
n (%) 2206 (14.09) 2378 (15.19) 3707 (23.68) 5014 (32.03) 2351 (15.02)
Age, years 61.5 ± 11.7 64.3 ± 10.7 67.3 ± 10.0 68.0 ± 9.5 69.6 ± 8.7 < 0.0001
Gender, n (%) < 0.0001
Females 833 (37.76) 948 (39.87) 1592 (42.95) 2270 (45.27) 1111 (47.26)
Males 1373 (62.24) 1430 (60.13) 2115 (57.05) 2744 (54.73) 1240 (52.74)
Smoking status, n (%) < 0.0001
Never 1220 (55.30) 1352 (56.85) 2059 (55.54) 2890 (57.64) 1328 (56.49)
Former 535 (24.25) 603 (25.36) 1084 (29.24) 1439 (28.70) 746 (31.73)
Current 451 (20.44) 423 (17.79) 564 (15.21) 685 (13.66) 277 (11.78)
Diabetes duration, years 10.7 ± 9.4 11.9 ± 9.7 13.3 ± 10.2 14.2 ± 10.4 14.4 ± 10.2 < 0.0001
HbA1c, mmol/mol 58.7 ± 17.5 58.9 ± 16.3 58.6 ± 16.8 59.1 ± 15.8 59.6 ± 16.3 < 0.0001
Anti-hyperglycemic treatment, n (%) < 0.0001
Lifestyle 393 (17.82) 424 (17.83) 481 (12.98) 587 (11.71) 228 (9.70)
Non-insulin 1310 (59.38) 1470 (61.82) 2244 (60.53) 3225 (64.32) 1370 (58.27)
Insulin 503 (22.80) 484 (20.35) 982 (26.49) 1202 (23.97) 753 (32.03)
BMI, kg/m2 27.29 ± 4.80 28.08 ± 4.72 29.08 ± 5.11 29.27 ± 5.09 30.61 ± 5.43 < 0.0001
Waist circumference, cm 99.1 ± 9.8 100.8 ± 9.6 102.7 ± 10.3 103.1 ± 10.3 105.8 ± 10.9 < 0.0001
Triglycerides, mmol/l 1.21 (0.88, 1.73) 1.28 (0.93, 1.83) 1.36 (0.98, 1.92) 1.36 (0.99, 1.90) 1.46 (1.07, 2.00) < 0.0001
Total cholesterol, mmol/l 4.85 ± 0.96 4.94 ± 1.0 4.64 ± 1.0 4.80 ± 0.98 4.67 ± 0.96 < 0.0001
HDL cholesterol, mmol/l 1.31 ± 0.36 1.34 ± 0.37 1.25 ± 0.35 1.29 ± 0.35 1.26 ± 0.34 < 0.0001
LDL cholesterol, mmol/l 2.89 ± 0.82 2.93 ± 0.85 2.67 ± 0.84 2.80 ± 0.84 2.66 ± 0.81 < 0.0001
Lipid-lowering therapy, n (%) 671 (30.42) 779 (32.76) 1945 (52.47) 2468 (49.22) 1375 (58.49) < 0.0001
Statins, n (%) 601 (27.24) 698 (29.35) 1804 (48.66) 2280 (45.47) 1271 (54.06) < 0.0001
Anti-platelet therapy, n (%) 402 (18.22) 454 (19.09) 1876 (50.61) 2167 (43.22) 1349 (57.38) < 0.0001
Anti-coagulant therapy, n (%) 25 (1.13) 31 (1.30) 226 (6.10) 180 (3.59) 207 (8.80) < 0.0001
Albuminuria, mg/24 h 10.3 (5.5, 18.9) 11.1 (5,8, 21.4) 13.8 (6.6, 37.2) 14.4 (7.0, 36.5) 19.8 (9.1, 73.4) < 0.0001
eGFR, ml·min−1·1.73 m−2 89.8 ± 18.4 86.9 ± 17.0 78.3 ± 21.3 78.6 ± 20.1 71.1 ± 22.6 < 0.0001
DKD phenotypes, n (%) < 0.0001
Alb−/eGFR− 1776 (80.51) 1861 (78.26) 2213 (59.70) 3068 (61.19) 1066 (45.34)
Alb+/eGFR− 275 (12.47) 352 (14.80) 737 (19.88) 1046 (20.86) 556 (23.65)
Alb−/eGFR+ 100 (4.53) 106 (4.46) 420 (11.33) 498 (9.93) 352 (14.97)
Alb+/eGFR+ 55 (2.49) 59 (2.48) 337 (9.09) 402 (8.02) 377 (16.04)
DR, n (%) < 0.0001
No 1883 (85.36) 1957 (82.30) 2862 (77.21) 3799 (75.77) 1688 (71.80)
Non-advanced 193 (8.75) 245 (10.30) 496 (13.38) 683 (13.62) 327 (13.91)
Advanced 127 (5.76) 176 (7.40) 349 (9.41) 532 (10.61) 336 (14.29)
CVD, n (%)
Any 214 (9.70) 253 (10.64) 1127 (30.40) 1196 (23.85) 830 (35.30) < 0.0001
Acute myocardial infarction 67 (3.04) 68 (2.86) 627 (16.91) 525 (10.47) 455 (19.35) < 0.0001
Coronary revascularization 63 (2.86) 69 (2.90) 588 (15.86) 468 (9.33) 391 (16.63) < 0.0001
Any coronary event 107 (4.85) 113 (4.75) 830 (22.39) 756 (15.08) 590 (25.10) < 0.0001
Stroke 28 (1.27) 38 (1.60) 147 (3.97) 173 (3.45) 127 (5.40) < 0.0001
Carotid revascularization 54 (2.45) 72 (3.03) 227 (6.12) 313 (6.24) 190 (8.08) < 0.0001
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with values between 130 and 139 and/or 80–89mmHg,
formerly assigned to the UCHT and UCRHT categories,
respectively, were included in these groups.
Association between resistant hypertension and mortality
(based on the 140/90mmHg BP targets)
Crude and age- and gender-adjusted mortality rates,
Kaplan–Meier estimates, and HRs were similar to those
observed when participants were stratified according to
the more stringent BP targets (Table 4, Additional file 2:
Figure S1B and Additional file 4: Figure S2), except that
(a) CHT was associated with a significantly lower risk of
death than RHT both in the unadjusted (0.78 [0.71–
0.86], P < 0.0001) and the adjusted (model 1: 0.86
[0.78–0.94], P = 0.001, and model 2: 0.90 [0.81–0.98],
P = 0.022, but not model 3: 0.99 [0.90–1. 08], P = 0.755)
analysis; and (b) the HRs for the CRHT and UCRHT
subgroups did not diverge appreciably (Additional file 5:
Figure S3).
Association between on-treatment BP values and
mortality
There was a U-shape association between on-treatment
BP values and all-cause mortality. In particular, using
the 130–139 mmHg category of systolic BP and the
80–89mmHg category of diastolic BP as reference, risk
Table 1 Baseline clinical features in the RIACE participants with valid information on vital status, stratified by BP status according to
the 130/80 mmHg BP targets (Continued)
Variable NT UTHT CHT UCHT RHT P
Any cerebrovascular event 79 (3.58) 109 (4.58) 346 (9.33) 458 (9.13) 300 (12.76) < 0.0001
Ulcer/gangrene/amputation 50 (2.67) 54 (2.27) 154 (4.15) 175 (3.49) 123 (5.23) < 0.0001
Lower limb revascularization 23 (1.04) 26 (1.09) 145 (3.91) 155 (3.09) 101 (4.30) < 0.0001
Any peripheral event 67 (3.04) 75 (3.15) 258 (6.96) 288 (5.74) 195 (8.29) < 0.0001
Aortic aneurysm 6 (0.27) 5 (0.21) 15 (0.40) 16 (0.32) 16 (0.68) 0.065
Cancer, n (%) 118 (5.35) 127 (5.34) 277 (7.47) 326 (6.50) 183 (7.78) < 0.0001
Values are mean ± SD or median (interquartile range) for continuous variables, and number of cases (percentage) for categorical variables. RIACE Renal Insufficiency And
Cardiovascular Events, BP blood pressure, NT normotension, UTHT untreated hypertension, CHT controlled hypertension (on-target with 1, 2, or 3 drugs), UCHT
uncontrolled hypertension (not on-target with 1 or 2 drugs), RHT resistant hypertension (on-target with > 4 drugs or not on-target with > 3 drugs), HbA1c hemoglobin
A1c, BMI body mass index, eGFR estimated glomerular filtration rate, DKD diabetic kidney disease, Alb
−/eGFR− no DKD, Alb+/eGFR− albuminuric DKD with preserved eGFR,
Alb−/eGFR+ nonalbuminuric DKD, Alb+/eGFR+ albuminuric DKD with reduced eGFR, DR diabetic retinopathy, CVD cardiovascular disease
Table 2 BP values and anti-hypertensive treatment in the RIACE participants with valid information on vital status, stratified by BP
status according to the 130/80 mmHg BP targets
Variable NT UTHT CHT UCHT RHT P
n, (%) 2206 (14.09) 2378 (15.19) 3707 (23.68) 5014 (32.03) 2351 (15.02)
Systolic BP, mmHg 121.2 ± 8.4 145.6 ± 12.7 122.1 ± 8.4 149.4 ± 14.2 147.2 ± 17.5 < 0.0001
Diastolic BP, mmHg 73.7 ± 6.7 82.4 ± 8.4 73.1 ± 7.3 82.6 ± 9.2 80.5 ± 9.7 < 0.0001
Pulse pressure, mmHg 47.5 ± 8.5 63.2 ± 14.4 49.0 ± 8.8 66.8 ± 14.9 66.7 ± 16.7 < 0.0001
Number of anti-hypertensive agents 0 ± 0 0 ± 0 1.80 ± 0.77 1.48 ± 0.50 3.47 ± 0.65 < 0.0001
RAS blockers, n (%) 0 (0) 0 (0) 3064 (82.65) 3989 (79.56) 2287 (97.28) < 0.0001
ACE-inhibitors, n (%) 0 (0) 0 (0) 2000 (53.95) 2651 (52.87) 1429 (60.78) < 0.0001
ARBs, n (%) 0 (0) 0 (0) 1085 (29.27) 1346 (26.84) 1144 (48.66) < 0.0001
Alpha-blockers, n (%) 0 (0) 0 (0) 200 (5.40) 240 (4.79) 507 (21.57) < 0.0001
Beta-blockers, n (%) 0 (0) 0 (0) 871 (23.50) 749 (14.94) 1099 (46.75) < 0.0001
Non-DHP CCBs, n (%) 0 (0) 0 (0) 247 (6.66) 285 (5.68) 257 (10.93) < 0.0001
DHP CCBs, n (%) 0 (0) 0 (0) 707 (19.07) 870 (17.35) 1243 (52.87) < 0.0001
Diuretics, n (%) 0 (0) 0 (0) 1410 (38.04) 1239 (23.71) 2013 (85.62) < 0.0001
Thiazides, n (%) 0 (0) 0 (0) 826 (22.28) 795 (15.86) 1387 (59.00) < 0.0001
Henle’s loop, n (%) 0 (0) 0 (0) 552 (14.89) 379 (7.56) 800 (34.03) < 0.0001
Anti-aldosterone, n (%) 0 (0) 0 (0) 172 (4.64) 100 (1.99) 301 (12.8) < 0.0001
Values are mean ± SD for continuous variables, unless otherwise specified. RIACE Renal Insufficiency And Cardiovascular Events, BP blood pressure, NT normotension,
UTHT untreated hypertension, CHT controlled hypertension (on-target with 1, 2, or 3 drugs), UCHT uncontrolled hypertension (not on-target with 1 or 2 drugs), RHT
resistant hypertension (on-target with > 4 drugs or not on-target with > 3 drugs), RAS renin-angiotensin system, ACE angiotensin-converting enzyme, ARBs angiotensin
receptor blockers, DHP dihydropyridine, CCBs calcium channel blockers
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Table 3 Baseline clinical features in the RIACE participants with valid information on vital status and resistant hypertension on-target
with > 4 drugs or not on-target with > 3 drugs according to the 130/80 mmHg BP targets
Variables CRHT UCRHT P
n (%) 305 (12.97) 2046 (87.03)
Age, years 68.0 ± 8.8 69.8 ± 8.6 0.001
Gender, n (%) 0.136
Females 132 (43.28) 979 (47.85)
Males 173 (56.72) 1067 (52.15)
Smoking status, n (%) 0.226
Never 159 (52.13) 1169 (57.14)
Former 104 (34.10) 642 (31.38)
Current 42 (13.77) 235 (11.49)
Diabetes duration, years 13.7 ± 9.8 14.5 ± 10.3 0.203
HbA1c, mmol/mol 60.7 ± 17.4 59.3 ± 16.1 0.208
Anti-hyperglycemic treatment, n (%) 0.008
Lifestyle 34 (11.15) 194 (9.48)
Non-insulin 153 (50.16) 1217 (59.48)
Insulin 118 (38.69) 635 (31.04)
BMI, kg/m2 30.5 ± 5.6 30.6 ± 5.4 0.702
Waist circumference, cm 105.6 ± 11.1 105.8 ± 10.9 0.804
Triglycerides, mmol/l 1.54 (1.08, 2.17) 1.44 (1.07, 1.97) 0.041
Total cholesterol, mmol/l 4.50 ± 0.94 4.71 ± 0.97 < 0.0001
HDL cholesterol, mmol/l 1.15 ± 0.30 1.28 ± 0.35 < 0.0001
LDL cholesterol, mmol/l 2.54 ± 0.77 2.69 ± 0.83 0.003
Lipid-lowering therapy, n (%) 188 (61.64) 1187 (58.02) 0.231
Statins, n (%) 175 (57.38) 1096 (53.57) 0.213
Anti-platelet therapy, n (%) 189 (61.97) 1160 (56.70) 0.082
Anti-coagulant therapy, n (%) 47 (15.41) 160 (7.82) < 0.0001
Albuminuria, mg/24 h 18.7 (9.2, 74.3) 20.0 (9.1, 72.9) 0.627
eGFR, ml·min−1·1.73 m−2 68.5 ± 24.1 71.5 ± 22.3 0.032
DKD phenotypes, n (%) 0.056
Alb−/eGFR− 127 (41.64) 939 (45.89)
Alb+/eGFR− 63 (20.66) 493 (24.10)
Alb−/eGFR+ 57 (18.69) 295 (14.42)
Alb+/eGFR+ 58 (19.02) 319 (15.59)
DR, n (%) 0.935
No 219 (71.80) 1469 (71.80)
Non-advanced 44 (14.43) 283 (13.83)
Advanced 42 (13.77) 294 (14.37)
CVD, n (%)
Any 136 (44.59) 694 (33.92) < 0.0001
Acute myocardial infarction 90 (29.51) 365 (17.84) < 0.0001
Coronary revascularization 78 (25.57) 313 (15.30) < 0.0001
Any coronary event 115 (37.70) 475 (23.22) < 0.0001
Stroke 10 (3.28) 117 (5.72) 0.079
Carotid revascularization 26 (8.52) 164 (8.02) 0.761
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of death increased for systolic BP < 120mmHg and dia-
stolic BP < 70mmHg, but not for values above 140 and
90mmHg, respectively, consistent with the previously
reported inverse association of mortality with systolic
and diastolic BP in this cohort (Fig. 3) [32].
Discussion
This analysis of the RIACE cohort of patients with type
2 diabetes shows that resistant hypertension was associ-
ated with an increased risk of all-cause mortality, which
however was progressively attenuated after adjustment
for confounders. In particular, using the 130/80 mmHg
targets, an increased risk of death in individuals with re-
sistant versus controlled hypertension was observed only
in the unadjusted analysis, whereas, using the 140/90
mmHg targets, it was maintained also in the adjusted
analysis, except when accounting for complications/co-
morbidities. These observations indicate that CVD risk
profile and particularly complications (indicating target
organ damage) and comorbidities, which are significantly
worse in individuals with resistant hypertension, drive
the increased risk of death associated with this condition
compared to controlled hypertension. However, our
finding that, in type 2 diabetes, resistant hypertension
does not predict death beyond target organ damage is at
odds with data from the general hypertensive population
[12–15, 18–21] and hypertensive individuals with CVD
[19, 20] or CKD [22, 23]. Indeed, in these studies,
diabetes was found to be an independent correlate of ad-
verse outcomes, suggesting that it poses a significantly
greater risk of death masking that associated with resistant
hypertension. This interpretation is consistent with a sub-
group analysis of the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) co-
hort, showing a significant association of resistant hyper-
tension with all-cause mortality in non-diabetic, but not in
diabetic individuals [18].
Another intriguing observation coming from our data
is that, among resistant hypertensive patients, those
on-target with > 4 drugs showed a higher mortality risk
than individuals not on-target with > 3 drugs. Again, this
finding is at variance with data from the general hyper-
tensive population [13, 14] and also with a retrospective
analysis of a group of US Veterans with resistant
Table 3 Baseline clinical features in the RIACE participants with valid information on vital status and resistant hypertension on-target
with > 4 drugs or not on-target with > 3 drugs according to the 130/80 mmHg BP targets (Continued)
Variables CRHT UCRHT P
Any cerebrovascular event 35 (11.48) 265 (12.95) 0.471
Ulcer/gangrene/amputation 18 (5.90) 105 (5.13) 0.573
Lower limb revascularization 20 (6.56) 81 (3.96) 0.037
Any peripheral event 30 (9.84) 165 (8.06) 0.295
Aortic aneurysm 3 (0.98) 13 (0.64) 0.490
Cancer, n (%) 30 (9.84) 153 (7.48) 0.152
Systolic BP, mmHg 121.3 ± 8.8 151.0 ± 15.0 < 0.0001
Diastolic BP, mmHg 72.4 ± 7.1 81.7 ± 9.5 < 0.0001
Pulse pressure, mmHg 48.8 ± 9.0 69.3 ± 16.0 < 0.0001
Number of anti-hypertensive agents 4.21 ± 0.45 3.36 ± 0.60 < 0.0001
RAS blockers, n (%) 304 (99.67) 1983 (96.92) 0.006
ACE-inhibitors, n (%) 195 (63.93) 1234 (60.31) 0.227
ARBs, n (%) 151 (49.51) 993 (48.53) 0.751
Alpha-blockers, n (%) 91 (29.84) 416 (20.33) < 0.0001
Beta-blockers, n (%) 223 (73.11) 876 (42.82) < 0.0001
Non-DHP CCBs, n (%) 31 (10.16) 226 (11.05) 0.645
DHP CCBs, n (%) 169 (55.41) 1074 (52.49) 0.341
Diuretics, n (%) 287 (94.10) 1726 (84.36) < 0.0001
Thiazides, n (%) 179 (58.69) 1208 (59.04) 0.907
Henle’s loop, n (%) 158 (51.80) 642 (31.38) < 0.0001
Anti-aldosterone, n (%) 87 (28.52) 2046 (10.46) < 0.0001
Values are mean ± SD or median (interquartile range) for continuous variables, and number of cases (percentage) for categorical variables. RIACE Renal Insufficiency And
Cardiovascular Events, CRHT controlled resistant hypertension (on-target with > 4 drugs), UCRHT uncontrolled resistant hypertension (not on-target with > 3 drugs),
HbA1c hemoglobin A1c, BMI body mass index, eGFR estimated glomerular filtration rate, DKD diabetic kidney disease, Alb
−/eGFR− no DKD, Alb+/eGFR− albuminuric DKD
with preserved eGFR, Alb−/eGFR+ nonalbuminuric DKD, Alb+/eGFR+ albuminuric DKD with reduced eGFR, DR diabetic retinopathy, CVD cardiovascular disease, BP blood
pressure, RAS renin-angiotensin system, ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, DHP dihydropyridine, CCBs calcium channel blockers
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hypertension, showing that controlling BP values re-
sulted in lower mortality compared with individuals who
remained uncontrolled over a 6-year follow-up [34].
However, in these studies, the BP values in participants
with controlled resistant hypertension were higher than
in our cohort, at least when the RIACE participants were
categorized using the 130/80 mmHg targets, i.e., when
differences in mortality between the two resistant hyper-
tensive subgroups were actually observed. This suggests
that our unexpected finding may be explained, at least
partly, by the quite low BP levels observed in controlled
resistant hypertensive individuals. Indeed, also patients
with non-resistant controlled hypertension showed BP
values well below target when using the 130/80 mmHg
goals for categorization, thus suggesting that low BP
levels might also contribute to explain the observation
that risk of death in these individuals was not signifi-
cantly lower than in patients with resistant hypertension
in the adjusted analyses. This interpretation is supported
by the higher mortality risk associated with lower BP
values regardless of group assignment, which is consist-
ent with the J-curve phenomenon occurring in high-risk
patients, such as those with established CVD, CKD, and/
or diabetes. In these individuals, an impaired blood flow
auto-regulation would elevate the BP threshold below
which organ perfusion is reduced [35]. This J-curve ef-
fect has been described in several post hoc analyses of
intervention trials in which however reverse causality
could not be excluded and was indeed suggested by the
evidence of a similar phenomenon in the placebo-treated
groups that calls into question its clinical relevance [35].
Data from the Taipei City Geriatric Health Examination
Database [36], the CLARIFY registry [37], and a cohort of
US Veterans [38] showed that low BP values are indeed
associated with increased mortality in community-dwell-
ing older adults and in individuals with CVD and CKD. A
previous study on hypertensive individuals with manifest
vascular disease reported a somewhat higher increase in
all-cause and CVD mortality risk versus controlled hyper-
tension in subjects with controlled resistant hypertension
than in those with uncontrolled resistant hypertension
[21] and another survey in hypertensive patients with
atherothrombosis showed that those poorly controlled
on ≥ 3 agents had an increased risk of stroke and
congestive heart failure, whereas those on ≥ 4
anti-hypertensive agents (irrespective of BP control)
had an increased risk of all adverse outcomes, includ-
ing all-cause mortality, except stroke [39]. Though
not originally designed to address this issue, our study
provides further support to the existence of a clinic-
ally meaningful J-curve effect, which may have in-
creased mortality risk among individuals with
controlled hypertension, thus masking the excess risk
associated with resistant hypertension.
Table 4 Mortality rates in the RIACE participants with valid information on vital status, stratified by BP status according to the
130/80 mmHg or 140/90 mmHg BP targets
N Events Percent events Events per 1000 patient-years
(95% CI) unadjusted




130/80 mmHg BP targets < 0.0001 < 0.0001
NT 2206 316 14.32 18.36 (16.33–20.38) 10.15 (8.64–11.92)
UTHT 2378 380 15.98 20.65 (18.57–22.73) 9.52 (8.17–11.10)
CHT 3707 980 26.44 36.67 (34.37–38.96) 14.39 (12.61–16.41)
UCHT 5014 1180 23.53 31.76 (29.94–33.57) 11.93 (10.50–13.55)
RHT 2351 746 31.73 44.94 (41.72–48.17) 15.68 (13.70–17.94)
CRHT 305 107 35.08 50.93 (41.28–60.58) 20.36 (16.34–25.38)
UCRHT 2046 639 31.23 44.08 (40.66–47.49) 15.07 (13.13–17.30)
140/90 mmHg BP targets < 0.0001 < 0.0001
NT 3445 492 14.28 18.31 (16.69–19.93) 9.72 (8.39–11.26)
UTHT 1139 204 17.91 23.31 (20.11–26.51) 9.86 (8.24–11.80)
CHT 6298 1619 25.71 35.44 (33.72–37.17) 13.61 (12.01–15.43)
UCHT 2952 707 23.95 32.26 (29.88–34.64) 11.82 (10.32–13.53)
RHT 1882 580 31.83 43.56 (40.01–47.10) 15.82 (13.76–18.18)
CRHT 559 173 30.95 43.93 (37.38–50.47) 17.15 (14.23–20.67)
UCRHT 1263 407 32.22 45.46 (41.04–49.88) 15.31 (13.18–17.77)
RIACE Renal Insufficiency And Cardiovascular Events, BP blood pressure, CI confidence interval; NT normotension, UTHT untreated hypertension, CHT controlled
hypertension (on-target with 1, 2, or 3 drugs), UCHT uncontrolled hypertension (not on-target with 1 or 2 drugs), RHT resistant hypertension (on-target with > 4 drugs or
not on-target with > 3 drugs), CRHT controlled resistant hypertension (on-target with > 4 drugs), UCRHT uncontrolled resistant hypertension (not on-target with > 3 drugs)
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A major strength of this study is that it is the first ana-
lyzing a type 2 diabetes population. Other strengths in-
clude the large sample size, the long-term follow-up, the
low number of participants lost to follow-up, and the sep-
aration of individuals with untreated or uncontrolled
hypertension from those with controlled hypertension
among participants without resistant hypertension. In fact,
patients with untreated or uncontrolled hypertension were
likely those with a recent diagnosis of hypertension or not
adequately treated, respectively. Presumably, they have
subsequently received a treatment or a more aggressive
one, thus experiencing a reduction of BP levels, though
some of them may have fallen into the resistant hyperten-
sive category. This would explain the relatively low mor-
tality rate in the untreated and, to a lesser extent,
uncontrolled hypertensive individuals, despite BP levels
being similar to those of patients with resistant hyperten-
sion, and also the finding that mortality risk did not in-
crease significantly with higher BP levels.
Among the limitations, lack of availability of multiple BP
measurements over time may have resulted in a misclassifi-
cation bias, as also some of the normotensive, controlled
hypertensive, and resistant hypertensive participants may
have switched to another BP status category during the
follow-up. Moreover, we acknowledge that true
treatment-resistant hypertension may have been misclassi-
fied with pseudo-resistance in a number of cases, as we
could not assess adherence and appropriate prescription of
anti-hypertensive therapy and to perform ambulatory BP
monitoring, the gold standard method for excluding white
coat hypertension. Indeed, ambulatory, but not office BP
was shown to be associated with CVD morbidity and
mortality in subjects with resistant hypertension, thus
highlighting the confounding role of pseudo-resistant
hypertension [40]. Another limitation is that not all the pa-
tients classified as resistant hypertensives were on a diur-
etic or a diuretic/CCB/RAS blocker combination, though
results did not change when only individuals meeting these
criteria were considered. This finding is consistent with the
results of the ALLHAT, in which prognoses in patients
with resistant hypertension were similar across treatment
groups, though participants assigned to chlorthalidone
were less likely to develop this condition [41]. More-
over, though use of anti-aldosterone therapy is not an
absolute criterion, prevalence of resistant hypertension
in our cohort might have been overestimated also be-
cause of the low proportion of resistant hypertensive
patients receiving this treatment (12.8 and 13.9%,
Fig. 1 Cox proportional hazards regression, unadjusted (a) and adjusted for age and gender (b) plus CVD risk factors (c) plus complications/
comorbidities (d), according to BP status (based on the 130/80mmHg BP targets). HRs (95% CI) for mortality are shown for each group. BP = blood
pressure; HR = hazard ratio; CI = confidence interval; NT = normotension (green); UTHT = untreated hypertension (blue); CHT = controlled hypertension
(on-target with 1, 2, or 3 drugs, red); UCHT = uncontrolled hypertension (not on-target with 1 or 2 drugs, purple); RHT = resistant hypertension (on-target
with > 4 drugs or not on-target with > 3 drugs, orange, reference)
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according to the 130/80 and 140/90 mmHg BP targets,
respectively), despite evidence that spironolactone is ef-
fective in reducing BP in resistant hypertensive individ-
uals [42], including those with diabetes [43]. Our
finding that use of anti-aldosterone agents was signifi-
cantly more frequent in controlled than uncontrolled
individuals with resistant hypertension militates in
favor of this interpretation. A further limitation is that
our main finding that resistant hypertension is not an
independent predictor of death beyond target organ
damage cannot be generalized until validated in at least
one independent type 2 diabetes population. Finally,
the observational design of the study makes causal in-
terpretation impossible.
Fig. 2 Cox proportional hazards regression, unadjusted (a) and adjusted for age and gender (b) plus CVD risk factors (c) plus complications/
comorbidities (d), according to BP status (based on the 130/80mmHg BP targets). HRs (95% CI) for mortality are shown for each group. BP = blood
pressure; HR = hazard ratio; CI = confidence interval; NT = normotension (green); UTHT = untreated hypertension (blue); CHT = controlled hypertension
(on-target with 1, 2, or 3 drugs, red); UCHT = uncontrolled hypertension (not on-target with 1 or 2 drugs, purple); UCRHT = uncontrolled resistant
hypertension (not on-target with > 3 drugs, pink); CRHT = controlled resistant hypertension (on-target with > 4 drugs, orange, reference)
Fig. 3 Age- and gender-adjusted HRs (95% CI) for mortality according to systolic (A) and diastolic (B) BP categories, regardless of group stratification
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Conclusions
In individuals with type 2 diabetes from the RIACE co-
hort, resistant hypertension did not predict death beyond
the increased burden of target organ damage characteriz-
ing this condition. In addition, risk of death was higher in
individuals with controlled resistant hypertension than in
those with uncontrolled resistant hypertension.
Both these findings are at variance with data from the
general hypertensive population and require confirmation
in other cohorts of patients with type 2 diabetes. They
may be related to the high mortality risk conferred by type
2 diabetes as well as to the detrimental effect of the low
BP values detected in individuals with controlled hyper-
tension (resistant and non-resistant), which may have
masked the increased risk associated with resistant
hypertension per se. The demonstration of a J-curve
phenomenon in our cohort further supports the concept
that less stringent BP goals may be preferable in individ-
uals with type 2 diabetes, especially in those at high CVD
and renal risk, though this issue is still a matter of debate.
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